Physician profile
Temeka Gillespie
NPI 1871659235
$2,176.14
in general payments reported to CMS, 2019-2025
14 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $242 · 2022: $533 · 2023: $447 · 2024: $501 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,401.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $786.71 | 2022-2025 | |
| Novo Nordisk INC | $249.64 | 2022-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $190.18 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.25 | 2021-2022 | |
| Madrigal Pharmaceuticals | $140.82 | 2024 | Rezdiffra |
| Otsuka America Pharmaceutical, INC. | $124.00 | 2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $114.59 | 2025 | Austedo Xr |
| Ardelyx, INC. | $112.16 | 2025 | Ibsrela |
| Janssen Pharmaceuticals, INC | $89.41 | 2022 | |
| Janssen Scientific Affairs, LLC | $88.00 | 2022 | |
| Paratek Pharmaceuticals, INC. | $86.78 | 2023 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $19.14 | 2021 | |
| Biogen, INC. | $17.03 | 2022 | |
| Ucb, INC. | $16.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Temeka Gillespie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.